A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of AD 4833-536 in Subjects With Type 2 Diabetes.
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Pioglitazone/azilsartan (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Takeda Global Research and Development Center
- 19 May 2010 New trial record